Stocks making the biggest moves premarket: Levi Strauss, GameStop, Twitter and more

Stocks making the biggest moves premarket: Levi Strauss, GameStop, Twitter and more


Check out the companies making headlines before the bell:

Levi Strauss (LEVI) – Levi Strauss rallied 3.9% in the premarket after reporting better-than-expected sales and profit for its latest quarter, helped by higher prices and strong demand for its denim offerings. Levi Strauss also raised its quarterly dividend by 20%.

GameStop (GME) – GameStop fell 5.6% in premarket trading after the video game retailer fired Chief Financial Officer Mike Recupero and told employees in an internal memo that it is cutting staff, as it tries to turn its business around.

Twitter (TWTR) – Twitter shares lost 4% in premarket action, following a Washington Post report that Elon Musk’s deal to buy Twitter may be in jeopardy. People familiar with the matter told the paper that Musk’s team doesn’t think Twitter’s figures on spam accounts are reliable, although officials defended their numbers in a call with reporters.

Upstart Holdings (UPST) – The lender’s stock plunged 16.3% in premarket trading after it said it would not meet already-reduced financial targets for its second quarter. Upstart points to a constrained lending marketplace as well as moves during the quarter to convert loans into cash.

Spirit Airlines (SAVE) – Spirit Airlines once again delayed a special shareholder meeting to vote on its planned merger with Frontier Group (ULCC), this time until July 15. The postponement comes as Spirit continues talks with both Frontier and rival suitor JetBlue (JBLU). Spirit jumped 3.2% in the premarket.

Occidental Petroleum (OXY) – Berkshire Hathaway (BRKb) bought another 12 million Occidental Petroleum shares, raising its stake in the energy producer to 18.7%. Occidental gained 2% in premarket action.

WD-40 (WDFC) – The lubricant maker reported a quarterly profit and sales that fell short of analyst forecasts, impacted by inflationary pressures and a number of global disruptions. Shares slumped 10.6% in the premarket.

Nu Skin Enterprises (NUS) – Shares of the health products company skid 4% in premarket trading after it gave lighter-than-expected guidance for the current quarter. Nu Skin cited several negative factors, including the Russia/Ukraine conflict, Covid-related factors in China and the general global economic downturn.

Kura Sushi (KRUS) – The Japanese restaurant chain operator’s stock surged 13% in the premarket after it reported an unexpected quarterly profit and raised its sales guidance for the full year.



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More